Patellar tendinopathy · Review · 2026
Does shockwave help jumper's knee, and does the type matter?
In this review of 13 studies, pain scores in the shockwave groups fell from about 5.2 to 2.7, and knee function scores rose from about 55 to 75 where measured. Comparison groups also improved, with pain going from about 4.9 to 3.8. Neither focused nor radial shockwave stood out as better.
Improved over time- studies in the review
- 13
- people whose pain was measured
- 530
- kinds compared: focused and radial
- 2
Good to know: Studies differed in devices, doses and session numbers, and many people also did exercises.
Friedman A, Spicer S, Garfinkle J, et al. Archives of Rehabilitation Research and Clinical Translation, 2026 · Read the paper ↗
How this study worked
What the trials used
- Focused and radial ESWT protocols
- Included trials varied in focused/radial modality, energy flux density, impulses, session number, follow-up and concurrent eccentric exercise. The review discusses this heterogeneity but does not supply one standardized regimen.
Who took part
People with jumper's knee in 13 randomised and non-randomised studies.
Side effects
The review describes shockwave as low-risk but did not count side effects across studies.
All the numbers and the full appraisal
The results, in numbers.
Systematic review of focused or radial ESWT for patellar tendinopathy. Thirteen studies (randomized and nonrandomized) included 530 participants for VAS and nine studies/369 participants for VISA.
VAS3 reported outcomes
Pain (VAS)
VAS Pooled pre/post mean values and standardized effect sizes
Across the ESWT arms (n=372), pooled mean VAS decreased 5.24 to 2.71; control arms (n=158) decreased 4.89 to 3.80. Within-arm Cohen d was −1.54 (95% CI −2.06 to −1.03) for ESWT and −0.48 (−0.76 to −0.20) for control; both p<0.01. The authors report subgroup heterogeneity difference p<0.01 (Q=12.67), but do not provide a pooled between-group change estimate/CI in accessible text.
Analysis details and source
Heterogeneity: control I²=32%; ESWT I²=89%. Across studies, focused/radial protocols and control types differ. This synthesis combines pre/post change and should not be read as an absolute causal effect. Source-reported within-arm Cohen d estimates are structured separately; they are not treatment contrasts. The Methods say all 13 studies reported VAS, but Table 2's Outcomes Measured column lists only VISA for Zwerver et al and Persson Krogh et al; the study and participant counts here are those printed in the text.
Pain (VAS), within ESWT arms
VAS Cohen's d (within-arm pre-post; 95% CI)
within-arm baseline-to-follow-up change in ESWT arms; not a between-arm treatment contrast
372 participants in this estimate
Source-reported within-arm pre/post Cohen's d -1.54 (95% CI -2.06 to -1.03; p <0.01) across 372 participants. This standardized within-arm change is not a causal ESWT-versus-control estimate.
Analysis details and source
Reported separately from pooled group means and the subgroup Q test. No pooled between-group change estimate with CI is supplied in accessible text.
Pain (VAS), within control arms
VAS Cohen's d (within-arm pre-post; 95% CI)
within-arm baseline-to-follow-up change in control arms; not a between-arm treatment contrast
158 participants in this estimate
Source-reported within-arm pre/post Cohen's d -0.48 (95% CI -0.76 to -0.2; p <0.01) across 158 participants. This standardized within-arm change is not a causal ESWT-versus-control estimate.
Analysis details and source
Reported separately from pooled group means and the subgroup Q test. No pooled between-group change estimate with CI is supplied in accessible text.
Victorian Institute of Sport Assessment (VISA)1 reported outcome
Patellar tendon function (VISA)
Victorian Institute of Sport Assessment (VISA) Pooled pre/post mean values and standardized effect sizes
Across ESWT arms (n=246), pooled mean VISA increased 54.65 to 74.86; controls (n=123) increased 54.90 to 63.16. Within-arm Cohen d was 1.76 (95% CI 0.90–2.62) for ESWT and 0.56 (0.02–1.11) for control; p<0.01 and p=0.04, respectively. Subgroup difference p=0.02 (Q=5.3); no pooled between-group change estimate/CI is provided in accessible text.
Analysis details and source
Heterogeneity: control I²=77%; ESWT I²=94%. Mean follow-up and protocol varied; focused-versus-radial superiority was not established. Source-reported within-arm Cohen d estimates are structured separately; they are not treatment contrasts.
VAS and VISA1 reported outcome
Focused versus radial ESWT
VAS and VISA Direct comparative narrative
One trial directly randomized focused and radial ESWT, each combined with eccentric training, and found no significant difference in VAS or VISA. Across evidence there was no consistent pattern showing one waveform superior.
Analysis details and source
The review states that the other studies used only one waveform, which prevented a pooled between-waveform comparison. Its own Tables 1 and 2, however, list Şah et al (2023) as a sham-controlled RCT with both a focused and a radial ESWT arm (78 patients); the review reports no focused-versus-radial result from that trial.
VISA2 reported outcomes
Patellar tendon function (VISA), within ESWT arms
VISA Cohen's d (within-arm pre-post; 95% CI)
within-arm baseline-to-follow-up change in ESWT arms; not a between-arm treatment contrast
246 participants in this estimate
Source-reported within-arm pre/post Cohen's d 1.76 (95% CI 0.9 to 2.62; p <0.01) across 246 participants. This standardized within-arm change is not a causal ESWT-versus-control estimate.
Analysis details and source
Reported separately from pooled group means and the subgroup Q test. No pooled between-group change estimate with CI is supplied in accessible text.
Patellar tendon function (VISA), within control arms
VISA Cohen's d (within-arm pre-post; 95% CI)
within-arm baseline-to-follow-up change in control arms; not a between-arm treatment contrast
123 participants in this estimate
Source-reported within-arm pre/post Cohen's d 0.56 (95% CI 0.02 to 1.11; p = 0.04) across 123 participants. This standardized within-arm change is not a causal ESWT-versus-control estimate.
Analysis details and source
Reported separately from pooled group means and the subgroup Q test. No pooled between-group change estimate with CI is supplied in accessible text.
How treatment was delivered
Included trials varied in focused/radial modality, energy flux density, impulses, session number, follow-up and concurrent eccentric exercise. The review discusses this heterogeneity but does not supply one standardized regimen.
The accessible narrative describes ESWT as having a favorable risk profile but does not provide a pooled adverse-event count. Evidence includes nonrandomized studies with moderate/serious risk of bias.
High statistical heterogeneity (VAS I²=89%; VISA I²=94% in ESWT arms), variable doses/devices/session counts and concurrent exercise, mixed study designs, and nonrandomized risk of bias. Pooled within-arm changes do not alone establish a causal treatment effect. The article text does not report a pooled between-group estimate with CI, and direct focused-vs-radial evidence is limited to one trial.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- High statistical heterogeneity (VAS I²=89%; VISA I²=94% in ESWT arms), variable doses/devices/session counts and concurrent exercise, mixed study designs, and nonrandomized risk of bias. Pooled within-arm changes do not alone establish a causal treatment effect. The article text does not report a pooled between-group estimate with CI, and direct focused-vs-radial evidence is limited to one trial.
Source-linked critical reading
Systematic review with meta-analysis
Technical source record
Read the full article, tables/captions, eligibility, all VAS/VISA pooled results, subgroup/modality narrative, risk-of-bias and GRADE, heterogeneity, limitations and conclusion. Did not infer unreported between-group pooled effects.
Scores improved in ESWT arms, but controls also improved and protocols varied. The review did not establish focused ESWT as consistently better than radial ESWT.
For patellar tendinopathy, how do focused and radial ESWT affect pain and function, and is either waveform better?
Systematic review and meta-analysis searched PubMed, Embase and Web of Science through May 27, 2025. Thirteen studies (mixed RCT and nonrandomized designs) were included.
Patellar tendinopathy populations across included studies; VAS analyses included 530 participants, VISA analyses 369.
Focused and radial ESWT protocols varied in dose, pulses, sessions and eccentric exercise co-care; no single regimen was standardized.
Comparators included sham/placebo, PRP, conservative treatment and no control; one trial directly compared focused with radial ESWT.
For VAS, ESWT arms (n=372) changed 5.24 to 2.71; control arms (n=158) 4.89 to 3.80. For VISA, ESWT (n=246) changed 54.65 to 74.86; control (n=123) 54.90 to 63.16. These are pooled pre/post means.
Within-arm standardized effects favored improvement in both ESWT and controls; subgroup difference tests were reported. Heterogeneity was high in ESWT arms. One direct waveform RCT found no significant focused/radial difference; no consistent superiority pattern emerged.
No pooled harms count was presented in accessible narrative.
VAS/VISA ESWT heterogeneity I² 89%/94%, variable protocols and co-care, mixed study design and observational bias; pooled within-arm changes do not establish causality.
Evidence may support ESWT as a treatment option but does not establish optimal modality/dose or superiority over focused/radial comparator.
Head-to-head RCTs should standardize waveform, energy, sessions, eccentric exercise, follow-up and harms reporting.
Read the original article.
Systematic Review and Meta-analysis Assessing the Effects of Focal and Radial Extracorporeal Shockwave Therapy on Pain and Function in Patellar Tendinopathy.
Friedman A, Spicer S, Garfinkle J, Tahir H. · Archives of rehabilitation research and clinical translation · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →